Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Julia Branch

Nurse Practitioner, Family Cumming, GA Nurse Practitioner

NPI 1033600341 CMS profile 10426824

1800 Northside Forsyth Dr Ste 370, Cumming, GA 30028

Open in the dashboard

General payments

$101,925

344 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julia Branch of Cumming, GA is reported in the CMS Open Payments database as having received $101,925 across 344 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63,154 140
2024 General $24,836 78
2023 General $10,831 70
2022 General $1,932 27
2021 General $1,172 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julia Branch
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Julia Branch were reported at $63,154. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Julia Branch Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,172 $124 $35–$379 $132
2022 $1,932 $141 $44–$430 $149
2023 $10,831 $154 $49–$476 $160
2024 $24,836 $165 $51–$504 $164
2025 $63,154 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $50,695 91 payments
  2. Merck Sharp & Dohme Corporation $24,139 55 payments
  3. Ferring Pharmaceuticals Inc. $7,840 29 payments
  4. Janssen Scientific Affairs, LLC $7,500 6 payments
  5. Dendreon Pharmaceuticals LLC $7,016 22 payments
  6. Pfizer Inc. $1,310 24 payments
  7. Sumitomo Pharma America, Inc. $552 20 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $545 26 payments
  9. AstraZeneca Pharmaceuticals LP $495 14 payments
  10. Myovant Sciences Inc. $426 11 payments
  11. Other $1,406 46 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $44,012 34 payments
  2. Travel and Lodging $30,044 81 payments
  3. Consulting Fee $19,454 12 payments
  4. Food and Beverage $7,499 213 payments
  5. Honoraria $900 2 payments
  6. Education $16 2 payments
Products named General payments · program years 2021–2025
  1. RYBREVANT $29,676 54 payments
  2. CARVYKTI $29,676 54 payments
  3. KEYTRUDA $24,090 53 payments
  4. ERLEADA $14,130 39 payments
  5. AKEEGA $12,271 23 payments
  6. PROVENGE $7,016 22 payments
  7. ADSTILADRIN Oncology $5,306 18 payments
  8. ADSTILADRIN Oncology $2,534 11 payments
  9. ORGOVYX Oncology $1,287 23 payments
  10. ORGOVYX Hormone Therapy $703 23 payments
  11. Other $4,374 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

606

Median for Nurse Practitioner: 389

Drug cost

$3,771,481

Median for Nurse Practitioner: $21,885

Branded share of claims

71.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 169 $2,451,757
Xtandi Enzalutamide Brand 42 $583,295
Nubeqa Darolutamide Brand 39 $499,360
Orgovyx Relugolix Brand 62 $160,912
Gemtesa Vibegron Brand 69 $46,327
Myrbetriq Mirabegron Brand 37 $23,119
Estradiol Generic 17 $2,192
Dutasteride Generic 39 $2,069
Trimethoprim Generic 12 $1,197
Tamsulosin Hcl Generic 61 $755

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$440,681

Of which drugs: $419,995

Medicare patients

154

Average age 77

Services billed

3,689

24 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 55%
Arthritis 45%
Ischemic heart disease 42%
Diabetes 27%
Chronic kidney disease 25%
Atrial fibrillation 19%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 11 2,460 $49,802
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 70 $9,891

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $6,800
$6,800 — —
ERLEADA
  • Janssen Biotech, Inc. $6,295
  • Janssen Scientific Affairs, LLC $25
$6,320 169 —
AKEEGA
  • Janssen Biotech, Inc. $6,110
  • Janssen Scientific Affairs, LLC $25
$6,136 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $4,613
$4,613 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $427
$427 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record